Scientist

MARIANNA HALASI, Ph.D (Permanent Resident)

Chicago ● 773-***-**** ● ***************@*****.*** ● LinkedIn: www.linkedin.com/in/mariannahalasi SUMMARY

A highly driven and focused scientist with expertise in cancer biology research and preclinical drug testing

A very productive and diligent multi-tasker with 17 publications in peer-reviewed journals including 12 first- author papers

Extensive hands-on experience with animal models of cancer, cell culture and biochemical techniques

Excellent managing and organizational skills: successfully supervised 5 students and managed 5 collaborations resulting in 4 publications

Worked on 4 projects as a commercialization and strategy consultant volunteer SKILLS

Mouse-based in vivo Techniques: handling, injections (subcutaneous, i.p., i.v.), tumor growth monitoring by caliper measurement, tumor/organ harvest and tissue processing, breeding and maintaining a mouse colony Cell Biology Techniques: mammalian cell culture, transfection, gene knockdown (siRNA/shRNA), production of adenoviral, lentiviral and retroviral particles, generation of stable cell lines, microscopy Biochemical Techniques: Western blotting, immunoprecipitation, protein expression and purification, ChIP, EMSA, flow cytometry, immunohistochemistry

Molecular Biology Techniques: bacterial transformation, DNA/RNA extraction, qRT-PCR Computer Skills: Microsoft Office, Canvas, GraphPad Prism, ImageJ, EndNote Language Skills: English, Hungarian (native)

RESEARCH EXPERIENCE

Postdoctoral Fellow 2012-present

Department of Medicine, University of Illinois at Chicago

Research focused on understanding the mechanism of Forkhead Box M1 (FOXM1) inhibitors and how FOXM1 confers chemoresistance in acute myeloid leukemia

Published 6 first-author peer-reviewed articles

Supervised 1 summer student

Ad Hoc Reviewer for the PLoS One Journal

Awarded T32 postdoctoral training grant, Ruth L. Kirschstein National Research Service Award, NIH Predoctoral Fellow/Graduate Student 2005-2012

Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago

Research focused on characterizing inhibitors of FOXM1 in vitro and in vivo

Published 6 first-author peer-reviewed articles and co-authored 5 peer-reviewed papers

Supervised 2 summer students and 1 rotation student

Graduate Student Council Representative

EDUCATION

Ph.D. in Biochemistry and Molecular Genetics, University of Illinois at Chicago 2005-2012 B.S. in Education with concentration in Biology, University of Debrecen, Hungary 1997-2003 M.S. in Biology with specialization in Genetics, University of Debrecen, Hungary 1997-2002 MARIANNA HALASI, Ph.D (Permanent Resident)

Chicago ● 773-***-**** ● ***************@*****.*** ● LinkedIn: www.linkedin.com/in/mariannahalasi RESEARCH COLLABORATIONS

Irum Khan Lab (University of Illinois at Chicago) 2015-present Research focused on examining the role of FOXM1 in mediating chemoresistance in leukemia

Manipulated FOXM1 expression by gene knockdown and overexpression in 3 leukemia cell lines to demonstrate that FOXM1 confers resistance to chemotherapy in AML, which resulted in a publication.

Khan I.*, M. Halasi*, M.F. Zia, P. Gann, S. Gaitonde, N. Mahmud, and A.L. Gartel. Nuclear FOXM1 drives chemoresistance in AML. Under review. (*Authors contributed equally). Jack L. Arbiser Lab (Emory University) 2014-present Research focused on how honokiol, a natural compound inhibits FOXM1

Analyzed 5 honokiol-treated cancer cell lines by Western blotting, luciferase reporter assay, qRT-PCR to delineate how honokiol suppresses FOXM1 expression, which resulted in a publication.

Halasi M., B. Hitchinson, R. Váraljai, E.V. Benevolenskaya, V. Gaponenko, J.L. Arbiser, and A.L. Gartel. Honokiol is a First Direct FOXM1 Antagonist. Under review. Elizaveta Benevolenskaya Lab (University of Illinois at Chicago) 2013-present Research focused on determining how proteasome inhibitors negatively regulate FOXM1

Performed Western blotting, transfection, flow cytometry, IP and ChIP to determine the unique and novel mechanism of FOXM1 suppression by proteasome inhibitors, which resulted in a publication.

Halasi M., R. Váraljai, E. Benevolenskaya, and A.L. Gartel. A novel function of molecular chaperon HSP70: suppression of oncogenic FOXM1 after proteotoxic stress. J Biol Chem. 2016. 291(1):142-8. Pradip K. Dudeja Lab (University of Illinois at Chicago) 2013-present Research focused on investigating the role of FOXM1 in the pathophysiology of colitis

Breed and treat mouse colonies to examine the protective role of FOXM1 against colitis development in vivo

Tested the effect of pro-inflammatory agents in 2 colon cancer cell lines and the effect of DSS treatment in the distal colon on FOXM1 protein expression by Western blotting. Vadim Gaponenko Lab (University of Illinois at Chicago) 2012-present Reseacrh focused on identifying, designing and testing short NPM inhibitory peptides

Purified FOXM1 and NPM recombinant proteins for NMR experiments.

Tested the inhibitory activity of 3 short NPM peptides in 5 human cancer cell lines by Western blotting, IP and colony formation assays.

SELECTED PUBLICATIONS (From 17)

Halasi, M., M. Wang, T.S. Chavan, V. Gaponenko, N. Hay, and A.L. Gartel. ROS inhibitor N-acetyl-L- cysteine antagonizes the activity of proteasome inhibitors. Biochem J. 2013. 454(2):201-8.

Halasi, M., B. Pandit, M. Wang, V. Nogueira, N. Hay, and A.L. Gartel. Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth. Am J Pathol. 2013. 183(1):257-65.

Halasi, M., and A.L. Gartel. FOX(M1) news - it is cancer. Mol Cancer Ther. 2013. 12(3):245-54. Review. CONSULTING EXPERIENCE

Commercialization and Strategy Consultant Volunteer 2015-present EnterpriseWorks Chicago, University of Illinois at Chicago

Worked in teams of 2-4 to evaluate commercialization options for 4 different innovations

Interviewed over 50 experts and conducted secondary research to explore technology capabilities

Presented 4 final deliverables with recommendation on potential commercial pathways of the project

Contact this candidate